Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real-world setting

Int J Dermatol. 2023 Jan;62(1):e31-e34. doi: 10.1111/ijd.16408. Epub 2022 Sep 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Arthritis, Psoriatic* / drug therapy
  • Humans
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • brodalumab
  • Antibodies, Monoclonal, Humanized